Analysts Are Bullish on Top Healthcare Stocks: Belite Bio, Inc. ADR (BLTE), CareCloud (CCLD)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Belite Bio, Inc. ADR (BLTE – Research Report), CareCloud (CCLD – Research Report) and Medicine Man Technologies (SHWZ – Research Report) with bullish sentiments.

Belite Bio, Inc. ADR (BLTE)

Benchmark Co. analyst Bruce Jackson maintained a Buy rating on Belite Bio, Inc. ADR today and set a price target of $57.00. The company’s shares closed last Wednesday at $42.45, close to its 52-week high of $48.60.

According to TipRanks.com, Jackson is ranked 0 out of 5 stars with an average return of -18.5% and a 31.9% success rate. Jackson covers the Healthcare sector, focusing on stocks such as Cardio Diagnostics Holdings, Tenon Medical, Inc., and Exact Sciences.

Belite Bio, Inc. ADR has an analyst consensus of Strong Buy, with a price target consensus of $56.50, representing a 34.5% upside. In a report issued on May 14, Leerink Partners also reiterated a Buy rating on the stock with a $50.00 price target.

See the top stocks recommended by analysts >>

CareCloud (CCLD)

In a report released today, Bill Sutherland from Benchmark Co. reiterated a Buy rating on CareCloud, with a price target of $4.00. The company’s shares closed last Wednesday at $2.23.

According to TipRanks.com, Sutherland has 0 stars on 0-5 stars ranking scale with an average return of -12.7% and a 32.6% success rate. Sutherland covers the Healthcare sector, focusing on stocks such as Cross Country Healthcare, AMN Healthcare Services, and ATI Physical Therapy.

CareCloud has an analyst consensus of Moderate Buy, with a price target consensus of $3.50.

Medicine Man Technologies (SHWZ)

Benchmark Co. analyst Mike Hickey maintained a Buy rating on Medicine Man Technologies today and set a price target of $2.50. The company’s shares closed last Wednesday at $0.51, close to its 52-week low of $0.43.

According to TipRanks.com, Hickey is a 1-star analyst with an average return of -2.6% and a 57.1% success rate. Hickey covers the NA sector, focusing on stocks such as TKO Group Holdings, AMC Entertainment, and Cinemark Holdings.

Currently, the analyst consensus on Medicine Man Technologies is a Moderate Buy with an average price target of $3.25.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on BLTE:

• Belite Bio Advances Retinal Disease Treatment
• Belite Bio reports Q1 EPS (33c), consensus (28c)
• Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update
• Belite Bio participates in a webinar with Cantor Fitzgerald
• Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results